ArticleTranslational psychiatry2026
Natural flavonoid dihydroquercetin blocks Trim14-JAK1-STAT3 signaling and relieves pain-depression comorbidity in rheumatoid arthritis.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is frequently complicated by chronic pain, anxiety and depression, yet the neuroimmune mechanisms linking peripheral inflammation to central affective dysfunction remain elusive. Here we demonstrate that the natural flavonoid dihydroquercetin (DHQ) blocks Trim14 and relieves pain-depression comorbidity in RA. Serum Trim14 is elevated in RA patients and correlates with clinical symptom severity. We identify Trim14 as a contributing factor of JAK1/STAT3 signaling in spinal dorsal horn neurons, promoting both nociceptive sensitization and affective symptoms in collagen-induced arthritis (CIA) mice. Intrathecal Trim14 siRNA attenuates synovial inflammation, inflammatory pain and anxiety-depressive behaviors. Molecular docking and molecular dynamics simulations reveal that DHQ occupies the Trim14 PRYSPRY substrate-recognition pocket with sub-micromolar affinity. Long-term DHQ treatment improves both nociceptive and affective symptoms by inhibiting spinal Trim14-JAK1-STAT3 axis in CIA mice. These findings suggest Trim14 as a potential neuroimmune target and DHQ as a natural medicine modulator for pain-depression comorbidity in chronic inflammatory disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.